1. A search was made for mechanisms which may exert a 'fine' control of the glucose 6-phosphate dehydrogenase reaction in rat liver, the rate-limiting step of the oxidative pentose phosphate cycle. 2. The glucose 6-phosphate dehydrogenase reaction is expected to go virtually to completion because the primary product (6-phosphogluconate lactone) is rapidly hydrolysed and the equilibrium of the joint dehydrogenase and lactonase reactions is in favour of virtually complete formation of phosphogluconate. However, the reaction does not go to completion, because glucose 6-phosphate dehydrogenase is inhibited by NADPH (Negelein & Haas, 1935) . 3. Measurements of the inhibition (which is competitive with NADP+) show that at physiological concentrations of free NADP+ and free NADPH the enzyme is almost completely inhibited. This indicates that the regulation of the enzyme activity is a matter of de-inhibition. 4. Among over 100 cell constituents tested only GSSG and AMP counteracted the inhibition by NADPH; only GSSG was highly effective at concentrations that may be taken to occur physiologically. 5. The effect of GSSG was not due to the GSSG reductase activity of liver extracts, because under the test conditions the activity of this enzyme was very weak, and complete inhibition of the reductase by Zn2+ did not abolish the GSSG effect. 6. Preincubationofthe enzyme preparation with GSSG in the presence of Mg2+ and NADP+ before the addition of glucose 6-phosphate and NADPH much increased the GSSG effect. 7. Dialysis of liver extracts and purification of glucose 6-phosphate dehydrogenase abolished the GSSG effect, indicating the participation of a cofactor in the action of GSSG. 8. The cofactor removed by dialysis or purification is very unstable. The cofactor could be separated from glucose 6-phosphate dehydrogenase by ultrafiltration of liver homogenates.
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Some properties of the cofactor are described. 9. The hypothesis that GSSG exerts a fine control of the pentose phosphate cycle by counteracting the NADPH inhibition of glucose 6-phosphate dehydrogenase is discussed.
The control of the pentose phosphate cycle is not yet fully understood. The main functions of the cycle are the supply of pentose phosphate for the synthesis of nucleotides and of reducing equivalents, in the form ofNADPH, for biosyntheses (e.g. of fatty acids) or, in erythrocytes, for the regeneration of haemoglobin from methaemoglobin. As these requirements are variable, regulatory mechanisms must be expected to adjust the rate of the cycle to changing needs. These are likely to operate at the initial step (the glucose 6-phosphate dehydrogenase reaction) and to take part in the control of the fate of glucose 6-phosphate, an intermediate which may form glycogen, glucose, fructose 6-phosphate or 6-phosphogluconate.
A major factor in the regulation of the glucose 6-phosphate dehydrogenase reaction is the adaptive change in the amount of this enzyme (and of 6-phosphogluconate dehydrogenase) first described by Tepperman & Tepperman (1958) , Fitch et al. * Deceased 13 January 1974. Vol. 138 (1959a,b) and Fitch & Chaikoff (1960) : in response to a diet containing excess of carbohydrate and causing a deposition of fat, the amount of the two dehydrogenases in the liver may increase 5-10-fold. These adaptive changes represent a 'coarse control'. In addition a 'fine control' is expected by which prompt variations in the enzyme activities can be brought about.
These considerations led us to investigate the factors that modify the activity of hepatic glucose 6-phosphate dehydrogenase, in particular the inhibitory action ofNADPH, discovered by Negelein & Haas (1935) . The experiments confirm that the inhibition by NADPH is competitively reversed by NADP+ and depends on the [NADPH]/ [NADP+] ratio. The inhibition approaches 100% when the ratio reaches a value of 9. In rat liver cytoplasm the ratio of the free nucleotides is of the order of 100 (Veech et al., 1969; Veech, 1968 
Experimental
Special substrates and crystalline enzymes were obtained from Boehringer Corp. (London) Ltd., London W.5, U.K. Solutions (1 mM) of NADPH and NADP+ were made fresh each day. To obtain crude enzyme preparations, weighed samples of tissues from Wistar rats were homogenized with 4vol. of ice-cold 0.1 M-potassium phosphate buffer, pH7.4, containing 1 mM-EDTA, and centrifuged at 30000g for 20min at 20C. The supernatants were stored at -20°C in sealed tubes. A crude yeast extract was made by rupturing the cells of freshly crumbled baker's yeast by rapid freezing (liquid N2) and thawing (25°C). This was once repeated and followed by centrifugation at 30000g for 20min at 2°C. The supernatant yeast extract was also stored at -200C.
Assay of glucose 6-phosphate dehydrogenase (EC 1.1.1.49) activity was carried out spectrophotometrically at 24-25°C in groups of four cuvettes containing 3ml of reactants, including (final concn.) 50mM-Tris-HCI buffer, pH7.4, 3.3mM-MgCl2, 1.33 mM-glucose 6-phosphate, various concentrations of NADP+ and NADPH, and samples of enzyme and tissue preparations freshly diluted with water. The amounts of tissue extracts added were the equivalent of 1-10mg fresh weight, depending on their activity. Crystalline yeast enzymes were diluted to about the same activity as the mammalian tissues. Two of the cuvettes were used to measure the extinction changes in the presence and absence of substrate, the other two to measure the effect of added NADPH in the presence and absence of substrate. The extinction changes in the absence of substrates and added NADPH were small but became substantial usually after addition ofNADPH. Corrections of the 'blanks' were important at very low NADP+ concentrations (less than 15 gM) when the total changes due to the dehydrogenase activity were small (0.030-0.050 extinction unit in the first 5 min).
Reactions were started by the addition of substrate, and spectrophotometer readings at 340 nm were taken during the linear period, which lasted about lOmin; later the reactions ceased to be linear mainly because of the fall in the concentration of NADP+. When reaction mixtures were preincubated this was carried out at 38°C in sealed polystyrene tubes. These were then cooled by shaking briefly in a water bath at 250C before being emptied into cuvettes.
The initial concentrations of the NADP+ solutions used in the assays were measured separately with glucose 6-phosphate and 5,1 (0.7 unit) of crystalline yeast glucose 6-phosphate dehydrogenase, and Tris-HCl buffer (50mM) at pH7.4. The reaction was usually complete within 2min.
Amicon tissuefiltrates
Amicon Centriflo membrane cones 224-CF-50A
[supplied by Amicon N.V., Oosterhout (N.B.),
Holland; see Blatt, 1971] were soaked for 2h in water before use. Tissue homogenates of various concentrations (5 ml) were centrifuged in the cones for 0.5-1 h at lOOOg and 4°C. Filtrates obtained were free ofglucose 6-phosphate dehydrogenase and GSSG reductase (EC 1.6.4.2) and, according to the makers, contained only substances of molecular weights below 50000. Some tissue preparations had a very high 'blank' activity, owing to the presence of endogenous substrates, and these were first removed by treating the preparation in a Minicon B-15 macro-solute concentrator (Amicon N.V.). According to the makers this removes substances of molecular weights below 15000.
Test systemfor 'cofactor' activity Two pairs of cuvettes were used as for the experiments on inhibition of glucose 6-phosphate dehydrogenase by NADPH. The concentrations of NADPH (added to one pair only) were 3.5-4 times those of NADP+. In addition to buffer and Mg2+ all cuvettes contained GSSG (100aJM) and ZnCI2 (33.3 jUM).
Glucose 6-phosphate was omitted from the blanks and the source of the dehydrogenase was rat liver supernatant from a 20% (w/v) homogenate, which had been dialysed for 24h against several changes of water at 2°C. This dialysed enzyme did not deteriorate for at least 2 months at -200C. Cuvettes contained the equivalent of 1.5-1.7mg of original liver. Extinction changes at 340nm were measured for 10 or 15min at room temperature (24-260C), with or without the addition of tissue extracts.
Conditions for comparing glutathione reductase and glucose 6-phosphate dehydrogenase activities in rat tissues Substrate concentrations were optimal, i.e. 1.33 mmglucose 6-phosphate and 0.33 mM-NADP+ in the dehydrogenase assay, and 0.33 mM-GSSG and 0.1 mM-NADPH in the reductase assay. Tris-HCI buffer (50mM, pH7.4) and 3.33mM-MgCI2 were included in the reaction mixture. Blanks without glucose 6-phosphate or GSSG were run simultaneously and the maximum linear rate of extinction changes at 340nm was measured for up to 6min at 250C after the addition of tissue homogenate. Rates The method of Klotzsch & Bergmeyer (1963) with crystalline GSSG reductase was used.
Assays ofGSH-cystine transhydrogenase (EC 1.8.4.4) The GSH-cystine transhydrogenase reaction in rat liver preparations was assayed by coupling it with added GSSG reductase, and measuring NADPH oxidation (see States & Segal, 1969 
Results
To investigate the effect of a variety of agents on the activity of glucose 6-phosphate dehydrogenase a test system was devised to contain a suitable range of concentrations of NADP+ and NADPH. Since the activity of the enzyme is measured by the increase in the concentration of NADPH, the range of inhibitory concentrations was limited. A further consideration in designing the experiments was the attempt to carry out the tests at coenzyme concentrations that are of the same order as those in liver in vivo (about 0.07mM-NADP+ and 0.30mM-NADPH). The latter concentration was found to be about three times higher than could be used experimentally.
The main source of the enzyme was the supernatant of rat liver because this tissue is one of the major sites of the pentose phosphate cycle. To obtain a measurable reaction rate the supernatant had to be diluted at least 1000-fold. This diluted the endogenous coenzymes to negligible amounts. It also diluted the substances that bind the coenzymes. Thus whereas in vivo the tissue concentrations of the coenzymes measured include free and protein-bound coenzymes, the concentrations in the experiments were virtually all those of free coenzymes. Vol. 138 Inhibition of liver glucose 6-phosphate dehydrogenase by NADPH Examples of the inhibition of the initial rate of the glucose 6-phosphate dehydrogenasereaction ( In contrast with GSSG, GSH had no effect when added at concentrations between 0.1 and mM. At 5mM there was a small decrease in the inhibition from 58 to 37 % but this was probably due to traces of contaminating GSSG, which are difficult to exclude owing to the ready autoxidation of GHS.
Formation ofGSSG in rat liver
The conversion of GSH into GSSG in animal tissues can be brought about by four different types of reactions: (1) by non-enzymic autoxidation catalysed by Fe2+, Cu2+ or Mn2+; (2) by nonenzymic interaction with dehydroascorbic acid; (3) by GSSG peroxidase (EC 1.11.1.9); (4) by GSH-disulphide transhydrogenases (EC 1.8.4.4, also EC 1.8.4.1, EC 1.8.4.2, EC 1.8.4.3, EC 1.8.5.1). The rate of the non-enzymic reactions is probably slight at the physiological concentrations of GSH, and in vivo the peroxidase reaction is probably the main source of GSSG. The rate of this reaction depends on the availability of substances which Vol. 138 on oxidation by 02 can form H202, such as hypoxanthine or uric acid. Table 5 shows that the addition of hypoxanthine, or uric acid, or DL-alanine in the presence of GSH, as expected, reverses the inhibition of glucose 6-phosphate dehydrogenase by NADPH. As the peroxidase is associated with microsomal particles, liver homogenates rather than supernatants were used as sources of enzymes. Hypoxanthine and uric acid arise continuously in animal tissues, and the concentrations of uric acid that were effective (0.033 mM) are lower than the uric acid concentrations that we find in freeze-clamped rat liver (0.07mM).
GSH-disulphide transhydrogenases (for references see States & Segal, 1973) Rat liver homogenate dialysed against frequent changes of water at 2°C showed no losses of either glucose 6-phosphate dehydrogenase or GSSG reductase activity, but after dialysis the addition of GSSG no longer reversed the inhibition of glucose 6-phosphate dehydrogenase by NADPH. To obtain a complete loss of the action of GSSG the dialysis had to be continued for 24h (Table 6 ). After 21 h there was still slight protection by GSSG. The GSSG effect was also lost when rat liver glucose 6-phosphate dehydrogenase was purified by the method of Bonsignore et al. (1970) (a procedure which also removed GSSG reductase activity). These experiments suggest that the counteraction by GSSG of the inhibition of glucose 6-phosphate by NADPH requires a cofactor.
1974 Assay ofcofactor The cofactor activity was tested with two pairs of cuvettes as described in the Experimental section for the measurement of the GSSG effect, except that the rat liver homogenate serving as a source of glucose 6-phosphate dehydrogenase was dialysed for 24h to remove the cofactor. ZnCl2 (33.3,M) was included to inhibit GSSG reductase, and GSSG (0.1 mM) was present in all cuvettes. NADPH, added to two cuvettes at concentrations about 3.5 times that of NADP+, gave inhibitions of glucose 6-phosphate dehydrogenase of 40-50% during the first 0min at 25°C, and addition of cofactor solution to all four cuvettes caused a reversal of the inhibition provided that GSSG was present. Thus both GSSG and the cofactor were necessary for the reversal of the inhibition (see Table 7 ).
Properties of the cofactor
The cofactor proved very unstable once it had been separated from the enzyme preparation. It was present in fresh HC104 filtrates, but the activity Vol. 138 disappeared rapidly in both acid and neutralized solutions. (NH4)2SO4 precipitation, heat (10min at 60°C or 5min at 100°C), storage at 4°C or -20°C, or evaporation to dryness in vacuo all caused the destruction of most of the activity. The most active cofactor solutions were obtained by centrifuging a 20 % homogenate for 0.5-1 h at lOOOg at 4°C in Amicon Centriflo membrane cones, which separate components below a molecular weight of 50000 from larger molecules (see Table 7 ). The filtrates obtained were free from glucose 6-phosphate dehydrogenase and GSSG reductase. Minicon treatment (see the Experimental section), which removes substances of molecular weights below 15000 without centrifugation, did not remove the cofactor from the homogenate, but removed it completely from the Amicon-cone filtrates.
Substantial (almost complete) reversals of the inhibition were obtained by addition of 5-10,1 of the Amicon-cone filtrates equivalent to 1-2mg fresh weight of liver (Table 7) . Under the test conditions the amount of dialysed liver providing the enzyme was equivalent to 1.6mg fresh weight. The GSSG content of the Amicon-cone filtrates was negligible (less than 1 % of the amount that had to be added for effectiveness). The Amicon-cone filtrates also contained an unidentified inhibitor of glucose 6-phosphate dehydrogenase, detectable when larger amounts of filtrate were used (Table 7) .
The stability of the Amicon-cone filtrates was not increased by the addition of glycerol, (NH4)2SO4, 2-mercaptoethanol, dithiothreitol or tetrahydrofolate or by changing the pH to 10.5 with glycine buffer. The most stable cofactor preparations were Amicon cone filtrates from 20 % rat liver homogenates stored in small sealed tubes at room temperature. These retain measurable cofactor activity for at least 3 weeks. Attempts to concentrate cofactor solutions in a desiccator over P205 at 2°C were unsuccessful. In contrast with the instability of the cofactor after its separation from the enzymes, the starting material (liver homogenates) could be stored indefinitely at -20°C without loss of cofactor activity.
Cofactor in other tissues
The cofactor activity of various rat tissues was tested with a 24h-dialysed rat liver homogenate as the test system. Amicon-cone filtrates were obtained from the tissues by the same procedure as was used with rat liver. With the exception of the lactating mammary gland all the tissues tested contained cofactor activities, though less than the liver (Table 8) . In cardiac muscle the activity was about one-third of that of liver. It was still lower in spleen, leg muscle, kidney, lung and brain. Table 8 shows that the cofactor activity was not in proportion to the glucose 6-phosphate dehydrogenase activities or GSSG reductase activity.
Attempts to identify the cofactor
The following substances were tested for cofactor activity, with negative results: thiamin pyrophosphate, folate, FAD, tetrahydrofolate, biotin, pyridoxal phosphate, cysteine, cystine, ascorbate, 2-mercaptoethanol, insulin, glucagon, intermediates of the tricarboxylic acid cycle, ATP, UTP, GTP, CTP, cyclic AMP, CoA, acetyl-CoA and combinations of these.
Inhibition and its reversal in other tissues
In all the rat tissues tested (see Table 8 ) glucose 6-phosphate dehydrogenase was inhibited by NADPH, and this was reversed by GSSG except in the case of lactating mammary gland. The other rat tissues lost their sensitivity to GSSG after centrifugation of homogenates for 1 h at lOOOg at 4°C in Amicon cones, but this could be partly or completely restored by addition of Amicon-cone filtrates from these homogenates.
Human tissues were more sensitive to very low concentrations of GSSG than were those of the rat. Thus preincubation for 15 min at 38°C with 3.3 am-GSSG substantially decreased NADPH inhibition in supernatants of human liver and kidney homogenates. In contrast with mammalian tissues, the glucose 6-phosphate dehydrogenase of yeast (crude extracts or crystalline enzyme) was not affected at all by GSSG or AMP, singly or together, with or without preincubation.
Seasonal variations of the GSSG effect
The rats used in most experiments had been kept in windowed constant-temperature rooms where Table 8 . Relative concentrations ofcofactor in rat tissues The relative content ofcofactor was assessed by determining the amounts of filtrate giving about the same effect. A dialysed rat liver preparation served as the test system. Amicon-cone filtrates of20% rat tissue homogenate were prepared as described in the Experimental section. Cuvettes contained GSSG (100,UM) and ZnC12 (33.3,UM) and 10-300pl of filtrates. The activities of glucose 6-phosphate dehydrogenase and GSSG reductase were assayed under optimal conditions in normal homogenates. The data, except for the mammary gland, are from the same rat. The glucose 6-phosphate dehydrogenase reaction has two special characteristics: first, the immediate product is a lactone, which is rapidly hydrolysed to 6-phosphogluconate. Owing to the large free-energy change of these two reactions (AG is estimated to be -37kJ at 25°C and pH7.0, and not much less at the metabolite concentrations in the liver; Bassham & Krause, 1969 ) the reaction would be expected to go virtually to completion. However, this is prevented by the second special property of the enzyme, the inhibition of the reaction by one of its products (NADPH), discovered for the yeast enzyme by Negelein & Haas (1935) and confirmed for the enzyme from other sources (Glock & McLean, 1953; Sapag-Hagar et al., 1973; . This inhibition is competitive with NADP+. By reversible inactivation of the enzyme it would establish a steady state in the glucose 6-phosphate dehydrogenases system that may be far removed from the thermodynamic equilibrium. On the basis of the concentrations of glucose 6-phosphate and 6-phosphogluconate reported by Sapag-Hagar et al. (1973) (Bassham & Krause, 1969) indicates an equilibrium constant of the reaction of the order of 10-6. Hence the difference between steady state and equilibrium is about 108. The steady state would behave, nevertheless, like a near-equilibrium system inasmuch as withdrawal of NADPH decreases the inhibition and causes the Vol. 138 withdrawn NADPH to be replaced. Thus the basic control of the first step of the pentose phosphate cycle may still be considered as a matter of nearequilibrium relations.
There are uncertainties about the absolute concentrations of free NADP and free NADPH in the tissue that limit precise quantitative predictions. The concentration of free plus bound NADPH in rat liver is of the order of 0.38mM (Williamson et al., 1971) . Since the ratio [free NADPH]/[free NADP+] in the liver is of the order of 100 (Veech et al., 1969; Gumaa et al., 1971) , it is probable that most of the total NADPH is in the free form; otherwise the concentration of free NADP+ would be exceedingly low (below 0.004mM). Concentrations giving effective inhibitions in the test system were as low as 20M (Table 1) , but despite the uncertainties there can be no doubt that the inhibition by NADPH occurs under physiological conditions.
That the rate of the pentose phosphate cycle is controlled at the glucose 6-phosphate dehydrogenase step has been established for some time (Cahill et al., 1958; Gumaa et al., 1971) . Further, since the concentration of glucose 6-phosphate exceeds by more than threefold the Km of glucose 6-phosphate dehydrogenase, Gumaa et al. (1971) concluded that control is not achieved by substrate limitation, but by NADP+ limitation. Although this is essentially correct, the position is more complex than previous authors had realized as they had not taken into account the virtually complete inhibition of hepatic glucose 6-phosphate dehydrogenase at physiological ratios of [free NADPH]/[free NADP+]. The value of this ratio (about 100) is much higher than the ratio for the total NAD phosphates. The almost complete inhibition implies that control of enzyme activity is essentially a matter of de-inhibition.
Effect of GSSG
GSSG has been implicated previously in playing a role in the regulation of the activity of glucose 6-phosphate dehydrogenase. Thus the increase in the rate of this reaction during phagocytosis by macrophages (Evans & Karnovsky, 1962) has been related to the increased H202 production during phagocytosis (Iyer et al., 1961; Paul & Sbarra, 1968) , H202 being instrumental in killing phagocytosed bacteria. The H202 is taken to be formed by an NADPH oxidase reaction (Paul & Sbarra, 1968) and, through GSH peroxidase, would convert some GSH into GSSG. The GSSG reductase would regenerate NADP+ from NADPH and thereby promote the glucose 6-phosphate dehydrogenase reaction (Reed, 1969) . However, this mechanism cannot be responsible for the effects of GSSG in the present system, because the effects occur even when GSSG reductase is absent or completely inhibited.
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The de-inhibition by GSSG is a possible, but not yet a proven, control mechanism of glucose 6-phosphate dehydrogenase in vivo. The difficulty in assessing the action of GSSG in vivo is the lack of reliable information on the tissue concentrations of GSSG (see Veech, 1968) . Veech (1968) found a mean GSSG concentration in freeze-clamped liver of 0.40mm and a mean concentration of GSH of 5.1mm. The values for GSSG are likely to be too high; thus Wendell (1970) , using N-ethylmaleimide to prevent oxidation of GSH, found 0.03-0.O5mM-GSSG and 3-4mM-GSH in perfused rat hearts. Wendell (1970) calculated the intracellular concentration of GSSG in rat liver to be about 0.06mM from the data of Guntherberg & Rapoport (1968) . Concentrations of GSSG required to obtain significant de-inhibitions are of the order of 0.01-0.1 mm under the conditions used in the present experiments. Still lower values are effective after preincubation. In experiments on human liver and kidney (not recorded) even 5 pM-GSSG reversed the NADPH inhibition.
Relative activities of glucose 6-phosphate and 6-phosphogluconate dehydrogenases Sapag-Hagar et al. (1973) found that the capacity of hepatic glucose 6-phosphate dehydrogenase is about five times greater under lipogenic conditions than the capacity of 6-phosphogluconate dehydrogenase. This 'imbalance' would be expected to cause an accumulation of 6-phosphogluconate, which, however, does not occur. Moreover, the competitive inhibition of 6-phosphogluconate dehydrogenase by NADPH was greater than that for glucose 6-phosphate dehydrogenase, the K1/Km values being 5 for glucose 6-phosphate dehydrogenase and 1.4 for 6-phosphogluconate dehydrogenase. SapagHagar et al. (1973) come to the tentative conclusion 'that either liver 6-phosphogluconate dehydrogenase can be markedly activated in situ by some as yet unrecognized factor (S factor) or there is an alternative pathway for 6-phosphogluconate in animal tissues'. In the light of the present experiments it is more likely that the adjustment of the activities of the two enzymes is achieved by control through deinhibition of the two enzymes.
Insufficient information is available on the properties ofhepatic glucose 6-phosphate dehydrogenase for a detailed analysis of the mechanism and of the kinetics of the effects of NADPH and GSSG. It is of interest that rat liver glucose 6-phosphate dehydrogenase occurs as a tetramer, dimer and monomer (Matsuda & Yugari, 1967) . The human erythrocyte enzyme has similar properties, and for this enzyme it has been shown that the dimer-monomer interconversion depends on the presence of 'structural' NADP+ (Wrigley et al., 1972; 
Organ differences
The fact that glucose 6-phosphate dehydrogenase of yeast and of mammary gland is insensitive to GSSG correlates with the reports that both the yeast enzyme (Yue et al., 1969) and the mammary-gland enzyme (Levy, 1963) do not contain bound NADP+. Further, these two enzymes are inactivated in the presence of2M-urea by dissociation to the monomers, whereas in crude rat liver the enzyme is hardly affected by urea. Both the yeast and mammary-gland enzymes, however, are inhibited by NADPH. The quantitative aspects of this inhibition and the question of de-inhibition remain to be investigated.
There may be good physiological reasons for organ differences. Unlike the liver enzyme the mammarygland enzyme functions more or less continuously during lactation, and 'coarse' control, increasing the amount of the enzyme during lactation, is no doubt the main regulatory mechanism. In liver rapid adjustments of enzyme activity are important because fatty acid synthesis shows diurnal variations apart from variations due to nutritional factors. In growing yeast cells the requirement for glucose 6-phosphate dehydrogenase activity (in connexion with a supply of ribose phosphate and of reducing equivalents) is also expected to be steady. In erythrocytes the demand for reducing equivalents probably depends mainly on the amounts of methaemoglobin to be reduced, which are liable to be variable.
